Aeterna Zentaris Inc. (TSE:AEZS – Get Rating)’s share price rose 5.2% during trading on Monday . The company traded as high as C$5.29 and last traded at C$5.24. Approximately 464 shares were traded during mid-day trading, a decline of 43% from the average daily volume of 818 shares. The stock had previously closed at C$4.98.
Aeterna Zentaris Price Performance
The company has a debt-to-equity ratio of 0.18, a quick ratio of 9.37 and a current ratio of 9.82. The company has a market cap of C$25.45 million and a PE ratio of -51.37. The firm’s fifty day moving average price is C$4.79.
Aeterna Zentaris Company Profile
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications.
- Is Walgreens Boots Alliance Earnings Miss Good For Investors?
- Why Warner Bros Discovery Is the S&P’s Hottest Stock
- Pinterest is the Social Commerce Platform to Watch in 2023
- 4 High-Yield Dividend Kings For 2023
- Will 2023 be a Good Year for Goodyear Tire Stock?
Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.